New stock news | Luping Pharmaceuticals submitted documents to the Hong Kong Stock Exchange Core product LP-168 is the world's first and only "covalent and non-covalent" dual BTK inhibitor.

According to the Wise Money Economics APP, on October 31st, the Hong Kong Stock Exchange revealed that Lu Peng Pharmaceutical Co., Ltd. has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC Securities as the exclusive sponsor.